Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label multinational Phase 3b/4 study of trastuzumab deruxtecan in previously treated HER2-positive metastatic breast cancer with or without brain metastases
2020-005048-46Phase 3Active
- Sponsor
- AstraZeneca
- Start
- Feb 2021
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of trastuzumab deruxtecan in HER2-positive breast cancer (2 cohorts), sponsored by AstraZeneca. Primary endpoints: Overall treatment effect of trastuzumab deruxtecan in HER2-positive metastatic breast cancer, Treatment effect on development and progression of brain metastases and 1 more. Started Feb 2021; status: active.
02
Drugs
trastuzumab deruxtecan
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on 2020-005048-46.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005048-46.